INCYTE CORP (INCY)
US45337C1027 - Common Stock
INCY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 602 industry peers in the Biotechnology industry. INCY gets an excellent profitability rating and is at the same time showing great financial health properties. INCY is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make INCY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
INCY had positive earnings in the past year.
In the past year INCY had a positive cash flow from operations.
Of the past 5 years INCY 4 years were profitable.
Of the past 5 years INCY 4 years had a positive operating cash flow.
1.2 Ratios
INCY has a better Return On Assets (6.65%) than 96.32% of its industry peers.
INCY's Return On Equity of 8.62% is amongst the best of the industry. INCY outperforms 95.32% of its industry peers.
With an excellent Return On Invested Capital value of 6.60%, INCY belongs to the best of the industry, outperforming 95.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.65% | ||
| ROE | 8.62% | ||
| ROIC | 6.6% |
ROA(3y)5.59%
ROA(5y)6.79%
ROE(3y)7.21%
ROE(5y)8.9%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 11.78%, INCY belongs to the best of the industry, outperforming 96.49% of the companies in the same industry.
In the last couple of years the Profit Margin of INCY has declined.
Looking at the Operating Margin, with a value of 14.96%, INCY belongs to the top of the industry, outperforming 96.32% of the companies in the same industry.
In the last couple of years the Operating Margin of INCY has declined.
With an excellent Gross Margin value of 93.84%, INCY belongs to the best of the industry, outperforming 94.15% of the companies in the same industry.
INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.96% | ||
| PM (TTM) | 11.78% | ||
| GM | 93.84% |
OM growth 3Y-3.31%
OM growth 5YN/A
PM growth 3Y-21.44%
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y-0.35%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so INCY is destroying value.
Compared to 1 year ago, INCY has more shares outstanding
INCY has more shares outstanding than it did 5 years ago.
The debt/assets ratio for INCY has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.32 indicates that INCY is not in any danger for bankruptcy at the moment.
INCY has a better Altman-Z score (6.32) than 83.95% of its industry peers.
INCY has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
The Debt to FCF ratio of INCY (0.05) is better than 97.49% of its industry peers.
INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
INCY has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INCY outperforms 44.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 6.32 |
ROIC/WACC0.6
WACC11.02%
2.3 Liquidity
A Current Ratio of 3.91 indicates that INCY has no problem at all paying its short term obligations.
With a Current ratio value of 3.91, INCY is not doing good in the industry: 60.03% of the companies in the same industry are doing better.
INCY has a Quick Ratio of 3.86. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
INCY's Quick ratio of 3.86 is in line compared to the rest of the industry. INCY outperforms 40.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.28% over the past year.
Measured over the past years, INCY shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.71% on average per year.
The Revenue has grown by 8.35% in the past year. This is quite good.
INCY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.18% yearly.
EPS 1Y (TTM)36.28%
EPS 3Y-0.71%
EPS 5YN/A
EPS growth Q2Q83.33%
Revenue 1Y (TTM)8.35%
Revenue growth 3Y16.29%
Revenue growth 5Y17.18%
Revenue growth Q2Q11.62%
3.2 Future
INCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.74% yearly.
Based on estimates for the next years, INCY will show a quite strong growth in Revenue. The Revenue will grow by 11.19% on average per year.
EPS Next Y31.33%
EPS Next 2Y29.84%
EPS Next 3Y29.5%
EPS Next 5Y25.74%
Revenue Next Year11.87%
Revenue Next 2Y11.77%
Revenue Next 3Y11.93%
Revenue Next 5Y11.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
INCY is valuated rather expensively with a Price/Earnings ratio of 17.33.
Based on the Price/Earnings ratio, INCY is valued cheaper than 96.66% of the companies in the same industry.
When comparing the Price/Earnings ratio of INCY to the average of the S&P500 Index (24.54), we can say INCY is valued slightly cheaper.
The Price/Forward Earnings ratio is 11.39, which indicates a very decent valuation of INCY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 98.16% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of INCY to the average of the S&P500 Index (19.65), we can say INCY is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.33 | ||
| Fwd PE | 11.39 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 96.15% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, INCY is valued cheaply inside the industry as 96.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.59 | ||
| EV/EBITDA | 12.98 |
4.3 Compensation for Growth
INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INCY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 29.50% in the coming years.
PEG (NY)0.55
PEG (5Y)N/A
EPS Next 2Y29.84%
EPS Next 3Y29.5%
5. Dividend
5.1 Amount
No dividends for INCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INCYTE CORP
NASDAQ:INCY (11/29/2023, 7:07:10 PM)
After market: 53.39 0 (0%)53.39
+0.69 (+1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2023-10-31/bmo
Earnings (Next)02-05 2024-02-05/amc
Inst Owners95.07%
Inst Owner Change0.95%
Ins Owners1.18%
Ins Owner Change8.66%
Market Cap11.97B
Analysts75.56
Price Target82.38 (54.3%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.39%
Min EPS beat(2)5.33%
Max EPS beat(2)17.46%
EPS beat(4)3
Avg EPS beat(4)-6.06%
Min EPS beat(4)-51.98%
Max EPS beat(4)17.46%
Revenue beat(2)1
Avg Revenue beat(2)-1.84%
Min Revenue beat(2)-6.5%
Max Revenue beat(2)2.82%
Revenue beat(4)2
Avg Revenue beat(4)-2.08%
Min Revenue beat(4)-7.72%
Max Revenue beat(4)3.1%
PT rev (1m)-2.84%
PT rev (3m)-1.92%
EPS NQ rev (1m)-5.3%
EPS NQ rev (3m)-6.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)-1.26%
Revenue NQ rev (3m)-1.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.33 | ||
| Fwd PE | 11.39 | ||
| P/S | 3.32 | ||
| P/FCF | 20.59 | ||
| P/OCF | 18.92 | ||
| P/B | 2.43 | ||
| P/tB | 2.58 | ||
| EV/EBITDA | 12.98 |
EPS(TTM)3.08
EY5.77%
EPS(NY)4.69
Fwd EY8.78%
FCF(TTM)2.59
FCFY4.86%
OCF(TTM)2.82
OCFY5.29%
SpS16.1
BVpS22
TBVpS20.73
PEG (NY)0.55
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.65% | ||
| ROE | 8.62% | ||
| ROCE | 10.26% | ||
| ROIC | 6.6% | ||
| ROICexc | 19.89% | ||
| ROICexgc | 23.77% | ||
| OM | 14.96% | ||
| PM (TTM) | 11.78% | ||
| GM | 93.84% | ||
| FCFM | 16.1% |
ROA(3y)5.59%
ROA(5y)6.79%
ROE(3y)7.21%
ROE(5y)8.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-18.21%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.83%
ROICexc growth 5YN/A
OM growth 3Y-3.31%
OM growth 5YN/A
PM growth 3Y-21.44%
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y-0.35%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 64.9% | ||
| Cap/Sales | 1.42% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.15% | ||
| Profit Quality | 136.71% | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.86 | ||
| Altman-Z | 6.32 |
F-Score5
WACC11.02%
ROIC/WACC0.6
Cap/Depr(3y)263.17%
Cap/Depr(5y)213.29%
Cap/Sales(3y)5.13%
Cap/Sales(5y)4.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)36.28%
EPS 3Y-0.71%
EPS 5YN/A
EPS growth Q2Q83.33%
EPS Next Y31.33%
EPS Next 2Y29.84%
EPS Next 3Y29.5%
EPS Next 5Y25.74%
Revenue 1Y (TTM)8.35%
Revenue growth 3Y16.29%
Revenue growth 5Y17.18%
Revenue growth Q2Q11.62%
Revenue Next Year11.87%
Revenue Next 2Y11.77%
Revenue Next 3Y11.93%
Revenue Next 5Y11.19%
EBIT growth 1Y-13.77%
EBIT growth 3Y12.44%
EBIT growth 5YN/A
EBIT Next Year49.42%
EBIT Next 3Y42.32%
EBIT Next 5Y24.97%
FCF growth 1Y6.92%
FCF growth 3Y12.14%
FCF growth 5YN/A
OCF growth 1Y-14.7%
OCF growth 3Y10.92%
OCF growth 5YN/A